Business
CANTAB used in EBBINGHAUS cognitive function trial
CANTAB used in EBBINGHAUS cognitive function trial.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6119Z Cambridge Cognition Holdings PLC 16 March 2017 \n\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\nCANTAB® assessments used in EBBINGHAUS cognitive function trial for Amgen's evolocumab\n \n16 March 2017: The neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health, today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.\nThe EBBINGHAUS researchers used Cambridge Cognition's CANTAB® digital cognitive assessments, an industry standard for cognitive outcomes measurement. CANTAB products are designed to improve data quality and operational efficiencies in large multinational clinical trials such as this.\nAmgen recently announced positive results of the FOURIER and EBBINGHAUS trials evaluating the human anti-PCSK9 monoclonal antibody evolocumab (Repatha®). The EBBINGHAUS trial is the first of its kind to prospectively explore the relationship between very low LDL cholesterol levels and neurocognitive function*.\nThe FOURIER trial conducted in 27,564 patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) found evolocumab reduced the risk of cardiovascular events, by reducing high levels of LDL cholesterol. The EBBINGHAUS cognitive function trial conducted in a subset of 1,974 FOURIER patients also achieved its primary endpoint, demonstrating that evolocumab was non-inferior to placebo for the effect on cognitive function. \nKenton Zavitz PhD, Director of Clinical Affairs, Cambridge Cognition commented: \"By all measures EBBINGHAUS is a landmark cognitive study. The study involved 1,974 patients across 30 countries worldwide using our tablet-based CANTAB cognitive technology. Researchers were able to reliably assess study subjects for effects on executive function, memory, and psychomotor speed at baseline and select time points. CANTAB software enabled assessments to be carried out in a patient-friendly manner and ensure consistent and reliable data capture that could be translated into meaningful results, without the need for a specialist in neuropsychology at each trial site.\" \nFull results from the evolocumab...